BIM
PTCT icon

Bogle Investment Management’s PTC Therapeutics PTCT Stock Holding History

Bogle Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-192,017
Closed -$9.03M – 403
2018
Q3 		$9.03M Buy
192,017
+35,619
+23% +$1.47M 0.65% 65
2018
Q2 		$5.28M Buy
156,398
+38,392
+33% +$1.2M 0.38% 99
2018
Q1 		$3.19M Sell
118,006
-42,026
-26% -$1.06M 0.24% 114
2017
Q4 		$2.67M Sell
160,032
-396,777
-71% -$6.72M 0.2% 131
2017
Q3 		$11.1M Sell
556,809
-53,112
-9% -$1.04M 0.76% 51
2017
Q2 		$11.2M Sell
609,921
-91,542
-13% -$1.23M 0.81% 42
2017
Q1 		$6.9M Sell
701,463
-55,025
-7% -$666K 0.48% 83
2016
Q4 		$8.25M Buy
756,488
+56,275
+8% +$590K 0.57% 67
2016
Q3 		$9.81M Buy
700,213
+442,534
+172% +$3.6M 0.71% 51
2016
Q2 		$1.81M Buy
+257,679
New +$1.89M 0.13% 185
2015
Q4 		– Sell
-25,976
Closed -$693K – 434
2015
Q3 		$693K Buy
+25,976
New +$1.11M 0.05% 288
2015
Q1 		– Sell
-28,494
Closed -$1.48M – 399
2014
Q4 		$1.48M Buy
+28,494
New +$1.25M 0.1% 228

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Bogle Investment Management's PTCT Position: Q4 2018 in Review

Bogle Investment Management sold out of PTC Therapeutics (PTCT) in Q4 2018, closing a stake of 192,017 shares — an estimated $9.03M sold.

Bogle Investment Management first reported a position in PTCT in Q4 2014 and held it in 12 quarters. The position peaked at $11.2M in Q2 2017. 164 funds tracked by Wall St. Rank hold PTCT as of Q4 2018.

  • Bogle Investment Management reported no remaining PTC Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Bogle Investment Management sold 192,017 PTC Therapeutics shares in Q4 2018, an estimated $9.03M.
  • Bogle Investment Management first reported a position in PTC Therapeutics in Q4 2014 and held it in 12 quarters.
  • Bogle Investment Management's PTC Therapeutics position peaked at $11.2M in Q2 2017.
  • 164 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2018.

Based on Bogle Investment Management's 13F filing for Q4 2018, filed 13 Feb 2019.